Whether you are an emerging novel technology developer or a large established manufacturer, commercializing and maintaining production of medical devices is a complex and risk-filled business.
Managing the production of biochemical reagents and formulations for your device can be particularly fraught with manufacturing challenges.
Sometimes, the production of these chemical components, with their associated, quality, regulatory, supply-chain, personnel, and expenditure challenges is better dealt with outside of your facilities. While the decision whether to outsource your manufacturing is business-critical, the choices become clearer as you analyze resource limitations, growth strategy and the complementary benefits, capabilities, and expertise of your potential external partner. In this webinar, we discuss the rational for moving your device production to a contract manufacturing organization (CMO) and detail the important considerations for vetting your new reagent and formulation partner. We will delve into characteristics of contract manufacturing, discuss how to choose a partner whose expertise aligns with your needs, and use case-studies to demonstrate how the right CMO can mitigate risk and deliver on your med device manufacturing operating plan.
The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.
Key Learning Objectives
- Understand the 10 most important drivers behind outsourcing
- Identify critical considerations when selecting an outsource partner
- Key outsourcing capabilities for Biochemical reagent and formulation from Merck
- Appreciate the potential advantages of outsourcing through example case studies
Target Audience
- Managers,
- Directors,
- Project Leaders,
- Developers,
- Outsourcing specialists,
- Supervisors
